Oxford Nanopore Technologies and A.D.A.M. Innovations (Japanese corporate name Genesis Healthcare Co.) announce an international collaboration to develop and deploy advanced genomic sequencing and medicine applications based on comprehensive, nanopore sequencing in Japan. In its initial phase, the collaboration has the potential to establish Oxford Nanopore?s information-rich, real-time sequencing technology across A.D.A.M. Innovations? advanced genetic testing portfolio, enabling rapid and precise genomic testing across multiple disease areas.

The goal of the collaboration is to introduce new clinical workflows under Japan-specific validation standards to support scalable sequencing of DNA fragments of any length for various conditions and diseases. Sequencing that captures complete genomic information will expand testing accuracy beyond what can be achieved through existing technologies. A Memorandum of Understanding was signed at the British Embassy in Tokyo, in an event supported by His Majesty?s Ambassador to Japan.

This collaboration brings together complementary strengths from the UK and Japan to expand genomic capabilities in Japan and support the country?s focus on earlier and more precise diagnosis. It aligns with the UK-Japan Health Memorandum of Cooperation and reflects a broader increase in bilateral life sciences collaboration supported by the UK Government?s Department for Science, Innovation and Technology (DSIT). By connecting innovation ecosystems in the UK and Japan, the initiative strengthens industrial cooperation and accelerates translational research for real-world patient benefit.